Mohit Bansal
Stock Analyst at Wells Fargo
(0)
# 2811
Out of 5,311 analysts
175
Total ratings
50.00%
Success rate
3.80%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
LLY Eli Lilly | Maintains: Overweight | 970 1100 | 719.82 | 52.82% | 17 | Mar 5, 2025 | |
GILD Gilead Sciences | Maintains: Overweight | 120 140 | 101.29 | 38.22% | 11 | Mar 5, 2025 | |
ABBV AbbVie | Maintains: Overweight | 210 240 | 174.06 | 37.88% | 8 | Mar 5, 2025 | |
BIIB Biogen | Maintains: Equal-Weight | 165 140 | 113.5 | 23.35% | 13 | Feb 13, 2025 | |
JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | 130 170 | 102.05 | 66.59% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 60 62 | 50.47 | 22.85% | 8 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 460 460 | 475.68 | -3.3% | 10 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 62 57 | 57.7 | -1.21% | 6 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1050 900 | 546.32 | 64.74% | 16 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 335 280 | 281.23 | -0.44% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 20.18 | 48.66% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 170 | 93.36 | 82.09% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 70 | 21.81 | 220.95% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 125 110 | 77.47 | 41.99% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 9 27 | 13.48 | 100.3% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 90 | 56.32 | 59.8% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 1 | 1100% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 28 30 | 21.56 | 39.15% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 140 170 | 90.72 | 87.39% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 30 40 | n/a | n/a | 1 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 30 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 27 | 12.18 | 121.67% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 50 | 30.67 | 63.03% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 60 | n/a | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 1875 | 5.61 | 33322.46% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 25 30 | 29.01 | 3.41% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 175 | n/a | n/a | 1 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 36 | 0.92 | 3813.04% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 125 225 | n/a | n/a | 4 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 16 19 | 14.71 | 29.16% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 5 | 0.22 | 2172.73% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 160 140 | n/a | n/a | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 30 60 | 1.2 | 4900% | 4 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 116 | n/a | n/a | 2 | Oct 2, 2017 |